海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated with Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
- prostate cancer metastatic MedDRA version: 18.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2015-06-01
Authorised
- A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with JNJ-63723283 in men with metastatic castration-resistant prostate cancer (mCRPC)
- Metastatic castration-resistant prostate cancer (mCRPC) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, Israel, Spain, United Kingdom, United States
- 2018-01-04
Authorised
- An international study to evaluate the effectiveness of Talazoparib in men with a genomic defect and metastatic castration-resistant prostate cancer who received previous chemotherapy and progressed on hormonal treatment
- Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, United Kingdom, United States
- 2016-09-15
Authorised
- ProBio : An outcome-adaptive and randomized multi-arm biomarker driven study in patients with metastatic castrate resistant prostate cancer (mCRPC)
- Metastatic castrate resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Sweden
- 2018-07-16
Authorised
- Phase II Safety and Efficacy of personalized lymphadenectomy or guided by Indocyanine Green (IGC) vs extended pelvic lymph node dissection in patients diagnosed with Prostate Cancer subsidiaries of Radical Prostatectomy and lymphadenectomy
- We want to study the relationship between the extent of lymphadenectomy and surgical complications. MedDRA version: 21.1 Level: LLT Classification code 10070467 Term: Pelvic lymphadenectomy System Organ Class: 100000004865 MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.1 Level: LLT Classification code 10068478 Term: Sentinel lymphadenectomy System Organ Class: 100000004865 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2020-01-14
Authorised
- A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Significant, Localised, Low- to Intermediate-Risk Prostate Cancer that is Associated with an MRI Lesion - Intraprostatic PRX302 injection to treat localised prostate cancer
- Prostate cancer br>MedDRA version: 19.0 Level: HLT Classification code 10036966 Term: Prostatic neoplasms and hypertrophy System Organ Class: 100000004872 ;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom, United States
- 2016-12-01
Authorised
- Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.
- Prostatic cancer patients who have received curative surgery.
- Norway
- 2010-03-30
Authorised
- A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Secondline Therapy in Men with Castrate Resistant Prostate Cancer. Estudio Fase III, randomizado, controlado con placebo, doble ciego que evalúa el beneficio clínico de añadir custirsen al retratamiento con docetaxel/prednisona como opción de tratamiento de segunda línea en varones con cáncer de próstata metastásico hormonoresistente - The prostate cancer Saturn study
- metastatic castrate resistant prostate cancer. cáncer de próstata metastásico hormonoresistente MedDRA version: 12.1 Level: LLT Classification code 10036909 Term: Prostate cancer metastatic MedDRA version: 12.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer
- Spain, United Kingdom
- 2010-08-12
Authorised
- A Phase II, Randomised, Open-label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of AZD0530 in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease Ensayo piloto, fase II, abierto y aleatorizado para evaluar la seguridad y los efectos de AZD0530 sobre la resorción ósea en pacientes con cáncer de próstata o de mama con metástasis óseas
- Prostate Cancer or Breast Cancer with Metastatic Bone Disease Cáncer de próstata o de mama con metástasis óseas
- Portugal, Spain, Sweden, United Kingdom
- 2007-12-27
Authorised
- PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (PCA): A PHASE III, SINGLE ARM MULTICENTRE STUDY. - Triptocare
- Locally advanced or metastatic prostate cancer br>MedDRA version: 12.0 Level: PT Classification code 10060862 Term: Prostate cancer
- Belgium, France, Italy, Latvia, Lithuania, Netherlands, Spain, United Kingdom
- 2009-09-11